Recent advances in targeting DNA repair pathways for the treatment of ovarian cancer and their clinical relevance.

about

PARI functions as a new transcriptional target of FOXM1 involved in gastric cancer development.Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy.

P2860

Q55023889-EBE10DDA-1746-4663-910F-1943DE63021D Q55041688-F522BF68-E9B9-4177-BE5C-4D9F96735A2C

P2860

Recent advances in targeting DNA repair pathways for the treatment of ovarian cancer and their clinical relevance.

Item

http://www.wikidata.org/entity/Q39309080

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Recent advances in targeting D ...... and their clinical relevance.

@en

Recent advances in targeting D ...... and their clinical relevance.

@nl

type

Item

label

Recent advances in targeting D ...... and their clinical relevance.

@en

Recent advances in targeting D ...... and their clinical relevance.

@nl

prefLabel

Recent advances in targeting D ...... and their clinical relevance.

@en

Recent advances in targeting D ...... and their clinical relevance.

@nl

P1476

Recent advances in targeting D ...... and their clinical relevance.

@en

P2093

Kenbun Sone

http://www.w3.org/2001/XMLSchema#string

Mayuyo Mori-Uchino

http://www.w3.org/2001/XMLSchema#string

Michihiro Tanikawa

http://www.w3.org/2001/XMLSchema#string

Tomoyuki Fujii

http://www.w3.org/2001/XMLSchema#string

Yutaka Osuga

http://www.w3.org/2001/XMLSchema#string

P2860

Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.

Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.

Integrated genomic analyses of ovarian carcinoma

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

P2888

s10147-017-1137-7

P304

611-618

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10147-017-1137-7

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Katsutoshi Oda

P577

2017-05-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28508305

http://www.w3.org/2001/XMLSchema#string

P921

ovarian cancer

Recent advances in targeting DNA repair pathways for the treatment of ovarian cancer and their clinical relevance.

about

P2860

P2860

Recent advances in targeting DNA repair pathways for the treatment of ovarian cancer and their clinical relevance.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921